Anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections are the treatment of choice for retinal diseases such as diabetic macular edema (DME), retinal venous occlusions, and age-related macular degeneration (AMD); millions of injections are administered annually, and due to the repeated injection guidelines, the risk of developing acute endophthalmitis could be increased [5]. The gene discussed is VEGFA; the disease is age-related macular degeneration.